Journal Article

Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment

Andreas Meyer, Laura-Anna Fischer, Marcel Fiedler, Markus A Kuczyk, Andreas Schneider, Jan Philipp Radtke, Gunther Klautke, Conrad Leitsmann, Felix Wezel, Daniel Porres, Philipp Krausewitz, Marcel Ott, Martina Becker-Schiebe, Hans Christiansen, Nina N Harke, Alexander Frismann, Christian Schwentner, Volker Zimmermanns, Oliver Micke, Christoph Käding, Kay Willborn, Mahmoud Farzat, Andreas Blana, Christian Bach, Christian Wagner, Sergiu Scobioala, Jörn H Witt, Hendrik A Wolff, Michael Truss, Alev Altay-Langguth, Matthias M Heck, Frank Bruns, Stefan Aufderklamm, Marie C Roesch, Michael Wittlinger, Daniel Wegener, Daniel Medenwald, Robert M Hermann, Emad Ezzibdeh, Inga Peters, Stephanie E Combs, Christoph Henkenberens, Felix Preisser, Rudolf Moritz, Kathrin Reichel, Boris A Hadaschik, Christina L Engels, Andrea Wittig, Stephan Buse, Sebastian Lettmaier, Samy Mahjoub, Sasa Pokupic, Andreas Manseck

2022

Overview

IntroductionSince the beginning of the pandemic in 2020, COVID-19 has changed the medical landscape. International recommendations for localized prostate cancer (PCa) include deferred treatment and adjusted therapeutic routines.Materials and methodsTo longitudinally evaluate changes in PCa treatment strategies in urological and radiotherapy departments in Germany, a link to a survey was sent to 134 institutions covering two representative baseline weeks prior to the pandemic and 13 weeks from March 2020 to February 2021. The questionnaire captured the numbers of radical prostatectomies, prostate biopsies and case numbers for conventional and hypofractionation radiotherapy. The results were evaluated using descriptive analyses.ResultsA total of 35% of the questionnaires were completed. PCa therapy increased by 6% in 2020 compared to 2019. At baseline, a total of 69 radiotherapy series and 164 radical prostatectomies (RPs) were documented. The decrease to 60% during the first wave of COVID-19 particularly affected low-risk PCa. The recovery throughout the summer months was followed by a renewed reduction to 58% at the end of 2020. After a gradual decline to 61% until July 2020, the number of prostate biopsies remained stable (89% to 98%) during the second wave. The use of RP fluctuated after an initial decrease without apparent prioritization of risk groups. Conventional fractionation was used in 66% of patients, followed by moderate hypofractionation (30%) and ultrahypofractionation (4%). One limitation was a potential selection bias of the selected weeks and the low response rate.ConclusionWhile the diagnosis and therapy of PCa were affected in both waves of the pandemic, the interim increase between the peaks led to a higher total number of patients in 2020 than in 2019. Recommendations regarding prioritization and fractionation routines were implemented heterogeneously, leaving unexplored potential for future pandemic challenges.

• Publisher: Public Library of Science (PLoS)